Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.33 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | BRS3 | P32247 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1605526 | 1.00 | JAK2 (0.36) | JAK2JAK1PDGFRBPDGFRAHRH4 | |
| SCHEMBL12573401 | 1.00 | JAK2 (0.36) | JAK2JAK1PDGFRBPDGFRAHRH4 | |
| SCHEMBL13492679 | 1.00 | JAK2 (0.36) | JAK2JAK1PDGFRBPDGFRAHRH4 | |
| SCHEMBL1604799 | 1.00 | JAK2 (0.36) | JAK2JAK1PDGFRBPDGFRAHRH4 | |
| SCHEMBL13542029 | 1.00 | JAK2 (0.36) | JAK2JAK1PDGFRBPDGFRAHRH4 | |
| SCHEMBL1604796 | 1.00 | JAK2 (0.36) | JAK2JAK1PDGFRBPDGFRAHRH4 | |
| SCHEMBL1605681 | 0.82 | JAK2 (0.36) | JAK2JAK1PDGFRBPDGFRACNR2 | |
| SCHEMBL14531548 | 0.82 | JAK2 (0.36) | JAK2JAK1PDGFRBPDGFRACNR2 | |
| SCHEMBL1605091 | 0.82 | HSD11B1 (0.40) | JAK2JAK1PDGFRBPDGFRAP2RX7 | |
| SCHEMBL1605690 | 0.82 | HSD11B1 (0.40) | JAK2JAK1PDGFRBPDGFRAP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541592-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 | AMGEN INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541593-B2 | Process for making substituted 2-amino-thiazolones | AMGEN INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541593-B2 | Process for making substituted 2-amino-thiazolones | AMGEN INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8536345-B2 | Process for making substituted 2-amino-thiazolones | AMGEN INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536345-B2 | Process for making substituted 2-amino-thiazolones | AMGEN INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20120010256-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB | 2012-01-12 | — | — | US | disclosed |
| US-20110160463-A1 | PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES | AMGEN INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110160463-A1 | PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES | AMGEN INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110082107-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC. | 2011-04-07 | — | — | US | disclosed |
| US-20100280255-A1 | PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES | AMGEN INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20080045503-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2008-02-21 | — | — | US | disclosed |
| US-20070281938-A1 | Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 | AMGEN INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070197598-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2007-08-23 | — | — | US | disclosed |
| US-7253196-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | AMGEN, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| WO-2007061600-A1 | CATALYZED PROCESS OF MAKING C-5-SUBSTITUTED HETEROCYCLIC INHIBITORS OF 11ß-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061661-A2 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070117985-A1 | Catalyzed process of making C-5-substituted heterocyclic inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 | AMGEN, INC. | 2007-05-24 | — | — | US | disclosed |
| EP-1753736-A2 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | Amgen Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060142357-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2006-06-29 | — | — | US | disclosed |
| WO-2005116002-A2 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082107-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD3B1, HSD17B1 | JAK2 4702/4885JAK1 3709/4885PDGFRB 4134/4885 |
| US-20080045503-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD3B1, HSD17B1 | JAK2 4702/4885JAK1 3709/4885PDGFRB 4134/4885 |
| US-20100280255-A1 | PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES | HSD11B1, HSD11B2, HSD17B1 | JAK2 3697/4885JAK1 2312/4885PDGFRB 4069/4885 |
| US-20070197598-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | JAK2 4534/4885JAK1 3089/4885PDGFRB 4042/4885 |
| US-20060142357-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD3B1, HSD17B1 | JAK2 4702/4885JAK1 3709/4885PDGFRB 4134/4885 |
| US-20120010256-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD3B1, HSD17B1 | JAK2 4702/4885JAK1 3709/4885PDGFRB 4134/4885 |
| US-20110160463-A1 | PROCESS FOR MAKING SUBSTITUTED 2-AMINO-THIAZOLONES | HSD11B1, HSD11B2, HSD17B1 | JAK2 3685/4885JAK1 2271/4885PDGFRB 3803/4885 |
| US-20070117985-A1 | Catalyzed process of making C-5-substituted heterocyclic inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 | SRD5A1, HSD11B1, HSD3B1 | JAK2 4563/4885JAK1 3871/4885PDGFRB 1452/4885 |
| US-20070281938-A1 | Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 | HSD11B1, HSD3B1, HSD17B1 | JAK2 4652/4885JAK1 3866/4885PDGFRB 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.